John Kollins, Satsuma Pharmaceuticals CEO
April 17, 2023 07:18 AM EDT
Deals

Japan­ese CRO buys back pen­ny stock spin­out while await­ing FDA de­ci­sion on mi­graine can­di­date

Amber Tong

Months af­ter an­nounc­ing it will not take on the com­mer­cial­iza­tion of its own mi­graine drug-de­vice, Sat­suma Phar­ma­ceu­ti­cals has found the buy­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times